2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Antibody Therapy, Natural Killer (NK) Cell Therapies, Transplantation, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Systems-Based Hematology, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, Translational Research, MDS, MPN, Clinical Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

1673 Combination of MAC-scoring with genetic risk scores improves outcome prediction to HMA/venetoclax in AML

Simon Renders, MD, Alexander Waclawiczek2, Ida Vänttinen, MSc, BSc3, Heikki Kuusanmäki, PhD4, Aino-Maija Leppä, MSc5, Mika Kontro, MD, PhD6, Michael Hundemer, MD7, Tim Sauer, MD8, Jiri Mayer, MD9, Carsten Müller-Tidow10, Andreas Trumpp, PhD, Prof11
1 DKFZ/ HI-STEM / Heidelberg University Hospital, Heidelberg, Germany
2 German Cancer research Center (DKFZ), Hi-STEM, Heidelberg, Germany
3 Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland
4 Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland
5 German Cancer research Center (DKFZ), Hi-STEM, Heidelberg, Germany
6 Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland
7 Heidelberg University Hospital, Heidelberg, Germany
8 Heidelberg University Hospital, Heidelberg, Germany
9 Masaryk University Hospital Brno, Brno, Czech Republic
10 Heidelberg University Hospital, Heidelberg, Germany
11 German Cancer research Center (DKFZ), Hi-STEM, Heidelberg, Germany

Background: Venetoclax combined with hypomethylating agents (VEN/HMA) has transformed treatment for older/unfit AML patients and is increasingly evaluated in younger, fit populations (Lu et al, Fathi et al., Blood, 2025). This development highlight the need for biomarkers guiding treatment decisions. Current genetic risk scores based on NGS and cytogenetics require 7-14 days for results, usually to late for treatment decision making (ELN2024, Döhner, Blood, 2024; PRISM, Lachowiez, JCO, 2026). To adress this, we have previously developed MAC-Score, a flow cytometry-based assay measuring BCL-2 family protein ratios (BCL-2 vs. MCL-1/BCL-xL) in GPR56+ leukemic stem cells, deliverable within 24 hours using standard 8-color flow cytometry (Waclawiczek et al, Cancer discovery, 2023). MAC-Scoring was initially established on 82 samples and above median MAC-Scores predicted HMA/VEN response with >95% accuracy

Methods: We retrospectively validated MAC-Score in 240 AML patients from three independent European cohorts (Germany, Czech Republic, Finland) treated with VEN/HMA as first-line (n=177) or salvage therapy (n=63). Patients were stratified as MAC-Score. high (score >0.4) or MAC-Score low (score ≤0.4). We compared MAC-Score performance against established risk scores and assessed predictive value across molecular subgroups and phenotypic classifications.

Results: In first-line therapy, MAC-Score high patients demonstrated superior response rates (93% vs. 53%), median EFS (24 vs. 4.3 months, p<0.001), and OS (31.2 vs. 6.7 months, p<0.001) compared to MAC-Score low patients. Multivariate analysis identified low MAC-Score as the strongest independent predictor of poor outcome (HR 3.2), surpassing 4-gene score classification (high benefit: HR 0.49) and similar to the effect of alloHCT status (HR 0.33). In salvage settings, MAC-Score high patients showed 85% vs. 40% response rates and prolonged EFS.

MAC-Score refined existing risk classifications: within NPM1-mutated patients, MAC-Score high identified long-term survivors (median EFS 721 days) versus early relapsers (189 days). Similarly, in IDH1/2-mutated AML, MAC-Score separated excellent (1178 days) from poor responders (189 days). Within the 4-gene intermediate and high-benefit groups, MAC-Score stratified outcomes significantly (intermediate: 506 vs. 130 days; high-benefit: 1178 vs. 189 days).
The added benefit of MAC-Scoring was also evident when using the PRISM risk score. While the general cohort reproduced the PRISM score, MAC-Scoring subdivided the "moderate"-risk group (median EFS 531 vs 41 days) as well as the "low" risk group (935 vs. 229 days), providing a rational to include phenotypic characterisation into mutation-based risk scores. In total, the EFS of MAC-low patients from any group was similar to that of patients with TP53 mutations.

MAC-Score also predicted outcome in monocytic AML patients (CD64+CD11b+) and extended the responde prediction for patients assessed by ex vivo drug sensitivity testing, improving risk discrimination across phenotypic and functional classifications. Data from additional cohorts will be included at the meeting.

Conclusions: This multicenter validation establishes MAC-Score as a clinically deployable biomarker for VEN/HMA response prediction. MAC-Scoring improves genetic models of outcome prediction and identifies excellent responders who may benefit from chemotherapy-sparing approaches as well as high-risk patients requiring treatment intensification or alternative strategies. Its 24-hour turnaround time enables timely treatment decisions at diagnosis. Prospective clinical implementation is ongoing. MAC-Scoring may help to guide patient selection for VEN/HMA-based versus intensive chemotherapy approaches, particularly in frontline trials evaluating treatment de-escalation strategies.

Simon Renders, MD: No relevant conflicts of interest to declare.